The Expression and Clinical Significance of Her-2/Neu and Ki-67 in Gastric Carcinoma
|School||Dalian Medical University|
|Keywords||Gastric Cancer Her-2/Neu Ki-67 Prognosis|
Background: Gastric cancer is a common malignant tumor in one of our country, the majority of patients are diagnosed at an advanced stage, poor prognosis and short survival, seriously affecting the health of our people, the factors associated with the prognosis of gastric cancer has been on much clinical attention. Gastric cancer, multiple genes involved in the development, multi-protein levels. Her-2/Neu is the proto-oncogene c-erbB-2 (Her-2/Neu) encoding the enzyme with receptor tyrosine (receptor-tyrosine kinase, RTKs) transmembrane glycoprotein activity can start tyrosine regulated kinase signal transduction system. Ki-67 is a nuclear protein having the characteristics of non-histone proteins, and cell mitosis, is the most widely used method for assessment of tumor cell proliferation. This study aimed to investigate the Her-2/Neu and Ki-67 in different types of gastric carcinoma cases, the relationship with clinicopathological features and prognosis relevance for clinical treatment and assessment of prognosis for reference. Objective: To detect Her-2/Neu and Ki-67 in different gastric tissues, analysis Her-2/Neu and Ki-67 expression and clinicopathological features and prognostic relevance of the impact, Her-2 / Neu and Ki-67 expression and the correlation between the effect on prognosis. Methods: Immunohistochemical two-step, detected in 60 patients with gastric cancer postoperative specimens Her-2/Neu and Ki-67 expression with clinical and pathological features and follow-up data were analyzed. Fourfold table using Chi-square test and Fisher's exact analysis Her-2/Neu and Ki-67 in different histological types of gastric cancer and whether there are differences; performed using Spearman rank correlation analysis, analysis Her-2/Neu and Ki -67, respectively, expression and clinicopathological features dual expression and correlation, using the Kaplan-Meier method and Log-rank test was used for survival analysis, analysis Her-2/Neu and Ki-67 expression and the pair were expressed in gastric cancer patients after disease-free survival and overall survival impact. Results: In 60 cases of gastric carcinoma Her-2/Neu and Ki-67 expression was positive were 29 cases (48.3%) and 31 cases (65%), both in the different histological types of gastric carcinoma without difference. 2.Her-2/Neu expression and depth of invasion, lymph node metastasis and clinical stage, Spearman correlation coefficient was 0.360 (P = 0.005), 0.321 (P = 0.012), 0.412 (P = 0.001). Her-2/Neu patients with positive expression of disease-free survival and median survival were significantly lower than those with negative expression. 3.Ki-67 expression and depth of invasion, clinical stage, Spearman correlation coefficient was 0.269 (P = 0.038), 0.265 (P = 0.041), Ki-67 expression was disease-free survival of patients and median survival were significantly lower than those with negative expression. 4.Her-2/Neu and co-expression of Ki-67-positive and clinical stage, Spearman correlation coefficient was 0.311 (P = 0.016), Her-2/Neu and co-expression of Ki-67-positive patients, the median survival was significantly lower in co-expression negative. 5 patients with gastric cancer Her-2/Neu and Ki-67 expression was positively correlated, r = 0.402, P value of 0.001, with statistical significance. Conclusion: 1.Her-2/Neu expression and tumor invasion, lymph node metastasis and TNM staging; Ki-67 expression and tumor invasion and TNM stage. Both were positive for expression in gastric cancer, and histological type. Survival analysis showed that, Her-2/Neu, Ki-67 positive expression survival worse than negative expression. 2.Her-2/Neu and Ki-67 expression in gastric cancer was positively correlated with the two co-expression with the TNM staging; coexpression positive inferior survival of patients with negative expression.